摘要
原发性肝癌是中国癌症第2大死因,其中肝细胞癌占80%~90%,各种治疗方法疗效欠佳,总体生存期较短。以免疫检查点抑制剂为核心的免疫治疗在肝细胞癌临床研究中表现出较好疗效,并获得相关指南支持。对于晚期肝细胞癌,免疫检查点抑制剂可单药或双药联用,可联合血管内皮生长因子抑制剂或酪氨酸激酶抑制剂。对早期和中期肝癌,免疫检查点抑制剂可联合局部治疗。此外,免疫细胞治疗也逐渐进入临床试验阶段。就肝细胞癌免疫治疗临床研究的最新进展进行综述,以期为临床应用和深入研究提供参考。
Primary liver cancer is the second leading cause of cancer death in China,of which hepatocellular carcinoma(HCC)accounts for 80%—90%.The therapeutic response of HCC is limited,with relatively disappointing overall survival.Immunotherapies,especially immune checkpoint inhibitors(ICI)have shown promising results in the systematic treatment of advanced or unresectable HCC with support by several guidelines.For advanced HCC,ICI can be used alone or in combination with another ICI,vascular endothelial growth factor inhibitors or tyrosine kinase inhibitors.For early-and middle-staged HCC,ICI could work with local-regional treatment.In addition,clinical trials evaluating the efficacy and safety of immune cell therapy are conducted.In this review,we summarized the latest progress of immunotherapy for HCC in order to provide some references for clinical application and further research.
作者
李靖华
杨丽惠
胡凯文
王婧筱
LI Jinghua;YANG Lihui;HU Kaiwen;WANG Jingxiao(Beijing University of Chinese Medicine,Beijing 100029,China;School of life Sciences,Beijing University of Traditional Chinese Medicine,Beijing 102401,China)
出处
《药物评价研究》
CAS
2022年第9期1725-1734,共10页
Drug Evaluation Research
基金
国家自然科学基金资助项目(82104651)
国家重点研发计划资助项目(2018YFC1705102)。
关键词
肝细胞癌
免疫治疗
免疫检查点抑制剂
免疫细胞治疗
临床研究
hepatocellular carcinoma
immunotherapy
immune checkpoint inhibitor
immune cell therapy
clinical study
